This article is more than 5 years old. Information may no longer be current.
BD receives funding for insulin infusion therapy improvements
BD will be entering into a new research partnership with JDRF to improve insulin infusion sets, according to a company press release.
“Insulin infusion therapy has substantial clinical benefits for type 1 diabetes management, yet its potential is limited by an abbreviated 3-day infusion set usage life,” Ken Miller, president of Diabetes Care for BD, said in the release. “Thanks to our latest partnership with JDRF, we can continue to build on the successful innovations BD currently offers in the insulin infusion category. We are extremely excited for this opportunity to advance the science and understanding of insulin delivery.”
This 2-year funding commitment from JDRF will allow BD to work on technology that will address the mechanical and biological issues that limit the infusion sets’ useful life.
Vincent Crabtree, PhD, director of research business development at JDRF, said in the release, “JDRF is pleased to continue our partnership with BD to further reduce the burden of managing infusion sets for people with type 1 diabetes. Living with diabetes is challenging, and JDRF’s goal is to provide broad access to innovative therapies, ensuring each person with this disease has access to treatments to enable them to have better outcomes and to lead healthy lives.”